Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients
| Autor: | Wang Chunsen, Zhang Rong, Huang Xiaobing, Dai Jingying, Yang Xi, Li Chenglong, Zheng Hong, Wang Xiaodong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Acute promyelocytic leukemia
Oncology medicine.medical_specialty Th1/Th17 QH301-705.5 Decitabine transplant relapse Biochemistry Genetics and Molecular Biology (miscellaneous) Biochemistry non-APL AML Internal medicine medicine Molecular Biosciences Biology (General) Survival rate Molecular Biology Original Research immune evasion business.industry Myeloid leukemia medicine.disease Transplantation Regimen epigenetic regimen Stem cell business Epigenetic therapy medicine.drug |
| Zdroj: | Frontiers in Molecular Biosciences, Vol 7 (2021) Frontiers in Molecular Biosciences |
| ISSN: | 2296-889X |
| DOI: | 10.3389/fmolb.2020.595395 |
| Popis: | To reverse the early-stage relapse post-hematopoietic stem cell transplantation, we investigated the safety and efficacy of a new epigenetic regimen (chidamide and decitabine plus thymalfasin simultaneously) on acute myeloid leukemia patients (excluding acute promyelocytic leukemia). Twenty-four patients were enrolled in this observational study during April 2015 to May 2018. The most common adverse event was reversible CTCAE grade 2 thrombocytopenia (20/24). Strikingly, all 24 patients had response to this epigenetic regimen accompanied with decreased measurable residual disease. The overall survival rate is 79.2% (19/24), with a relapse-free survival rate of 79.2% (19/24). During this regimen treatment, Th1 cells and CD3+CD4-CD8+T cells increased, and Th17 cells decreased gradually. The status of high Th1 and low Th17 cells was still observed on the 3rd month after discontinuation of this regimen. Interestingly, the significantly elevated ratio of Th1/Th17 seemed to reflect the treatment-related immune effect, which may be a valuable marker to be monitored in the early-relapse stage for evaluating the efficacy and prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|